Low-dose radiation response of the p21WAF1/CIP1 gene promoter transduced by adeno-associated virus vector

Experimental and Molecular Medicine

Volumn 38, Issue 5, 2006, Pages 553-564

  Nenoi, Mitsuru ^a   Daino, Kazuhiro ^b   Ichimura, Sachiko ^a   Takahashi, Shin Ichiro ^c   Akuta, Teruo ^d  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c UNIVERSITY OF TOKYO   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cyclin dependent kinase inhibitor p21; Dependovirus; dTMP kinase; Gene therapy; Promoter regions (genetic); Radiation; Simplexvirus

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; UNCLASSIFIED DRUG;

ADENOVIRUS VECTOR; ARTICLE; BREAST CANCER; CANCER CELL; ELECTROPORATION; GENE THERAPY; HUMAN; HUMAN CELL; LOW ENERGY RADIATION; PROMOTER REGION;

ADENO-ASSOCIATED VIRUS; DEPENDOVIRUS; SIMPLEXVIRUS;

EID: 33750734233     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2006.65     Document Type: Article

References (40)

1. Amundson SA, Lee RA, Koch-Paiz CA, Bittner ML, Meltzer P, Trent JM, Fornace AJ Jr. Differential responses of stress genes to low dose-rate gamma irradiation. Mol Cancer Res 2003;1:445-52
2. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53:3369-73
3. Braastad CD, Han Z, Hendrickson EA. Constitutive DNase I hypersensitivity of p53-regulated promoters. J Biol Chem 2003;278:8261-8
4. Caspari T. How to activate p53. Curr Biol 2000;10:R315-7
5. Daino K, Ichimura S, Nenoi M. Early induction of CDKN1A (p21) and GADD45 mRNA by a low dose of ionizing radiation is due to their dose-dependent post-transcriptional regulation. Radiat Res 2002;157:478-82
6. Drittanti L, Jenny C, Poulard K, Samba A, Manceau P, Soria N, Vincent N, Danos O, Vega M. Optimised helper virus-free production of high-quality adeno-associated virus vectors. J Gene Med 2001;3:59-71
7. Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, Fisher KJ, Engelhardt JF. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998;72:8568-77
8. Effert PJ, McCoy RH, Walther PJ, Liu ET. p53 gene alterations in human prostate carcinoma. J Urol 1993;150: 257-61
9. Effert PJ, Neubauer A, Walther PJ, Liu ET. Alterations of the p53 gene are associated with the progression of a human prostate carcinoma. J Urol 1992;147:789-93
10. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25
11. Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 2001;8:57-69
12. Fei P, El-Deiry WS. p53 and radiation responses. Oncogene 2003;22:5774-83
13. Giles KM, Daly JM, Beveridge DJ, Thomson AM, Voon DC, Furneaux HM, Jazayeri JA, Leedman PJ. The 3′-untranslated region of p21WAF1 mRNA is a composite cis-acting sequence bound by RNA-binding proteins from breast cancer cells, including HuR and poly(C)-binding protein. J Biol Chem 2003;278:2937-46
14. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW, Weichselbaum RR. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995;1:786-91
15. Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kieback CC, Kaplan A, Kaufman RH, Ramzy I, Aguilar-Cordova E, Kieback DG. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000;7:839-44
16. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53
17. Huser D, Weger S, Heilbronn R. Kinetics and frequency of adeno-associated virus site-specific integration into human chromosome 19 monitored by quantitative real-time PCR. J Virol 2002;76:7554-9
18. Kirn DH. A phase II trial of intratumoral injection with a selectively replicating adenovirus (ONYX-15) in patients with recurrent, refractory squamous cell carcinoma of the head and neck. In: Walther W, Stein U, eds. Methods in Molecular Medicine, Vol. 35: Gene Therapy: Methods and Protocols, Totowa, NJ: Humana Press; 2000, 559-74
19. Konishi F, Maeda H, Yamanishi Y, Hiyama K, Ishioka S, Yamakido M. Transcriptionally targeted in vivo gene therapy for carcinoembrionic antigen-producing adenocarcinoma. Hiroshima J Med Sci 1999;48:79-89
20. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000;106:763-71
21. Lepik D, Jaks V, Kadaja L, Varv S, Maimets T. Electroporation and carrier DNA cause p53 activation, cell cycle arrest, and apoptosis. Anal Biochem 2003;318:52-9
22. Li XS, Rishi AK, Shao ZM, Dawson MI, Jong L, Shroot B, Reichert U, Ordonez J, Fontana JA. Posttranscriptional regulation of p21WAF1/CIP1 expression in human breast carcinoma cells. Cancer Res 1996;56:5055-62
23. Liu J, Shen X, Nguyen VA, Kunos G, Gao B. Alpha(1) adrenergic agonist induction of p21(waf1/cip1) mRNA stability in transfected HepG2 cells correlates with the increased binding of an AU-rich element binding factor. J Biol Chem 2000;275:11846-51
24. Makinen K, Loimas S, Wahlfors J, Alhava E, Janne J. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer. J Gene Med 2000;2:361-7
25. Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, Ohno T. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther 1998;9:1409-17
26. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 2000;7:511-7
27. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, Iwaki Y, Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998;5:938-45
28. Miao CH, Snyder RO, Schowalter DB, Patijn GA, Donahue B, Winther B, Kay MA. The kinetics of rAAV integration in the liver. Nat Genet 1998;19:13-5
29. Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, Peabody T, Senzer N, Chu K, Rasmussen CS, Kessler PD, Rasmussen HS, Warso M, Kufe DW, Gupta TD, Weichselbaum RR. A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 2004;10:5747-53
30. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-69
31. Nenoi M, Ichimura S, Mita K, Yukawa O, Cartwright IL. Regulation of the catalase gene promoter by Sp1, CCAAT-recognizing factors, and a WT1/Egr-related factor in hydrogen peroxide-resistant HP100 cells. Cancer Res 2001;61:5885-94
32. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004;22:592-601
33. Surosky RT, Urabe M, Godwin SG, McQuiston SA, Kurtzman GJ, Ozawa K, Natsoulis G. Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 1997;71:7951-9
34. Uchida T, Wada C, Shitara T, Egawa S, Koshiba K. Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer. Br J Cancer 1993;68:751-5
35. Vincent-Lacaze N, Snyder RO, Gluzman R, Bohl D, Lagarde C, Danos O. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J Virol 1999;73:1949-55
36. Weichselbaum RR, Kufe DW, Hellman S, Rasmussen HS, King CR, Fischer PH, Mauceri HJ. Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 2002;3:665-71
37. Worthington J, Robson T, Murray M, O'Rourke M, Keilty G, Hirst DG. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Ther 2000;7:1126-31
38. Worthington J, Robson T, O'Keeffe M, Hirst DG. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. Gene Ther 2002;9:263-9
39. Worthington J, McCarthy HO, Barrett E, Adams C, Robson T, Hirst DG. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med 2004;6:673-80
40. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72:2224-32